Trusted Resource for Clinical Trials, Protocols & Progress
Sponsors should pilot eConsent and digital platforms in Tier-1 hospitals before scaling to Tier-2 sites. Early engagement with ethics committees and patient advocacy groups can address trust and usability concerns. CROs play a critical role in training site staff and monitoring compliance. SOPs should cover digital tool validation, data privacy, and audit readiness.
Click to read the full article.
Sponsors can reduce delays by:
✔️ Engaging the NMPA early through pre-IND consultations
✔️ Preparing ethics submissions in parallel with IND filings
✔️ Partnering with CROs to support Tier-2 hospital activation
✔️ Establishing SOPs for recruitment and monitoring
✔️ Leveraging accelerated pathways for oncology, vaccine, and rare disease trials
These practices help align Chinese timelines with global benchmarks.
Click to read the full article.
Sponsors should integrate China into global clinical development plans earlier, leveraging NMPA’s acceptance of multinational data. Early engagement with regulators through pre-IND consultations helps clarify expectations. CRO partnerships are critical for ensuring site readiness, ethics compliance, and inspection preparedness. Establishing harmonized SOPs across global and Chinese sites prevents compliance gaps.
Click to read the full article.
Sponsors should plan pharmacology studies with early engagement of NMPA and ethics committees. Selecting accredited Phase I units, ensuring robust CRO partnerships, and validating EDC systems are essential. Patient and volunteer safety should remain central, with clear SOPs for adverse event management and informed consent.
Click to read the full article.
Sponsors should design global trials to include adequate Chinese representation, reducing the need for bridging. Early engagement with the NMPA helps clarify bridging expectations and avoid delays. Using PK/PD modeling and simulation can also support waivers by demonstrating equivalence across populations. CRO partnerships enhance trial execution and regulatory compliance.
Click to read the full article.
Sponsors should integrate diversity goals into trial design, selecting sites beyond Tier-1 hospitals and adapting informed consent materials for local languages and literacy levels. CRO partnerships can support rural recruitment, while decentralized trial models can reduce participation burdens. Patient advocacy engagement should be embedded into recruitment strategies to build trust and ensure ethical inclusivity.
Click to read the full article.
Sponsors should engage the NMPA early through pre-IND consultations, select accredited Phase I units with strong safety infrastructure, and implement robust pharmacovigilance systems. CRO partnerships are essential for operational support, particularly in site readiness and data management. Early patient advocacy engagement improves recruitment and trust in high-risk early-phase studies.
Click to read the full article.
Sponsors should implement robust PV systems with validated databases, clear SOPs, and trained safety staff. Collaborating with CROs ensures compliance with reporting timelines and active monitoring. Establishing risk communication channels with patients and healthcare providers improves reporting quality. Regular mock inspections help organizations prepare for NMPA audits.
Click to read the full article.
Sponsors should engage IRBs early, providing comprehensive documentation and patient-friendly consent forms. Training for investigators and IRB members ensures understanding of GCP and international standards. Using CRO support and participating in centralized review pilots can mitigate delays and variability.
Click to read the full article.
Sponsors should:
✔️ Establish local servers for trial data and TMF systems
✔️ Partner with CROs with validated local IT infrastructure
✔️ Train staff on PIPL and HGRAC requirements
✔️ Plan early for cross-border transfer approvals
✔️ Use anonymization and encryption to reduce compliance risks
✔️ Engage with regulators proactively on sensitive data issues
These practices reduce delays and ensure data acceptance for global submissions.
Click to read the full article.
